PolarityTE Inc. acquired a preclinical biomedical research facility to develop its pipeline products.
The facility, a contract research organization, is fully functional and compliant with the Good Laboratory Practices and United States Department of Agriculture standards, the biotechnology company said.
The CEO and chairman of the company, Denver Lough, said "the purchase … integrates a new arm of the company — PolarityRD — which will function as an advanced CRO to help drive the field of biotechnology to deliver on the promise of exciting emerging technology."
The Salt Lake City-based biotech is developing a range of regenerative tissue products and biomaterials for use in medicine, biomedical engineering and material sciences.
